BILL ANALYSIS

HR6609

BEARISH

Pharmacists Fight Back in Medicare and Medicaid Act

HR6609 (Pharmacists Fight Back in Medicare and Medicaid Act) has been assessed with a bearish outlook for investors. This legislation directly affects Cigna Group ($CI), CVS Health ($CVS), Elevance Health ($ELV) and UnitedHealth Group ($UNH). The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bearish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR6609 targets PBM rebate retention and steering in Medicare/Medicaid — structurally bearish for $CVS, $CI, $UNH, but currently stalled in committee with zero progress in 5 months.

Market data shows 3-10% weekly and 8-42% monthly gains across affected tickers — the rally is driven by earnings and sector rotation, not legislative risk.

No near-term action expected. The bill requires passage through two House committees, full House, Senate, and signature — a low-probability path in the current Congress.

How HR6609 Affects the Market

Current prices ($CVS $83.3, $CI $287.69, $UNH $367.09, $ELV $372.94) reflect no material discount for HR6609 risk. The market is correctly assessing this as a low-probability, early-stage bill with a distant effective date (2027). However, if the bill gains unexpected momentum (e.g., committee markup scheduled, new cosponsor wave, Senate companion introduced), expect immediate repricing of these tickers to the downside by 2-5%. For now, the broader tailwinds (earnings, sector rotation) dominate price action. Investors should monitor Committee on Energy and Commerce calendar for any hearing or markup announcement — that would be the first real signal of legislative movement.

Bill Details

Metric	Value
Bill Number	HR6609
Market Sentiment	bearish
Event Date	December 11, 2025
Affected Sectors	Healthcare
Affected Stocks	Cigna Group ($CI), CVS Health ($CVS), Elevance Health ($ELV), UnitedHealth Group ($UNH)
Source	View on Congress.gov →

Summary

HR6609 is an early-stage bill that would mandate rebate pass-throughs and ban patient steering by PBMs in Medicare and Medicaid. The bill has 36 cosponsors but remains in committee since December 2025 with no further action — legislative probability is low near-term. Despite real headwinds for CVS, CI, UNH, and ELV, the market has rallied these names 3-10% in the past week and 8-42% in 30 days on unrelated earnings and sector rotation, not this bill.

Full AI Market Analysis

1) WHAT HAPPENED: On December 11, 2025, Rep. Auchincloss (D-MA) introduced HR6609, the 'Pharmacists Fight Back in Medicare and Medicaid Act'. The bill would amend the Social Security Act to require PDP sponsors and their PBMs in Medicare Part D and Medicaid to pass through 100% of manufacturer rebates to the plan at the point of sale, and prohibit steering patients to PBM-owned or affiliated pharmacies. It has 36 cosponsors (bipartisan) and was referred to the Energy & Commerce and Ways & Means Committees. There have been zero actions since referral — the bill is stalled in early-stage committee review. 2) THE MONEY TRAIL: This bill authorizes no direct government spending. It is a regulatory mandate — it imposes compliance requirements on private entities (PBMs and health plans). The financial impact is a transfer of value from PBM margins to plan sponsors, beneficiaries (lower cost-sharing), and independent pharmacies. For the affected PBMs, the revenue impact is the loss of rebate spreads (estimated 1-3% of drug spend) and steering-related pharmacy profits. No appropriation is involved. 3) STRUCTURAL WINNERS AND LOSERS: Losers are the vertically integrated PBMs: CVS (Caremark, $83.3), CI (Express Scripts, $287.69), and UNH (Optum Rx, $367.09) — these derive significant profit from rebate retention and steering. ELV ($372.94) is less exposed as it lacks a large captive PBM but still faces compliance costs. Winners would be independent pharmacies (not publicly traded in aggregate) and potentially retail pharmacy chains not affiliated with major PBMs (Rite Aid, if still public; Walgreens ($WBA)). The bill does not directly benefit drug manufacturers. 4) MARKET DATA REALITY: Despite this legislative overhang, all four tickers have rallied strongly over the past 30 days: CVS +15.98%, CI +7.85%, UNH +35.66%, ELV +27.39%. Over 7 days: CVS +6.88%, CI +4.37%, UNH +3.43%, ELV +8.17%. These moves coincide with broader healthcare sector rotation and earnings releases — the market is essentially ignoring this bill as legislative noise at this stage. 5) TIMELINE: The bill has been dormant for nearly five months. It needs committee markups in both Energy & Commerce and Ways & Means, House floor passage, Senate introduction/passage, and presidential signature. The effective date (2027) is still two years out. Near-term legislative probability is below 10%. This is a monitoring item, not a trading catalyst.